DECONGESTANT MARKET ANALYSIS

Decongestant Market, By Product Type (Tablets, Capsules, Nasal Sprays and Others), By Type of Decongestant (Oral Decongestants ( Pseudoephedrine, Phenylephrine and Others), Nasal Decongestants ( Oxymetazoline, Xylometazoline, Phenylephrine, Naphazoline and Others)), By Mode of Action (Alpha-Adrenergic Agonists, Vasoconstrictors, and Others), By Application (Seasonal Allergic Rhinitis, Perennial Allergic Rhinitis, Sinusitis, Nasal Congestion, Cold and Flu and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Hyper Market/Super Market), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

Recent Developments:

Research and Development:

In March 2023, Marinomed Biotech AG, an Austrian science-based biotech company, announced positive results from its clinical study on the decongestant effect of the sorbitol-containing carragelose nasal spray.

Product launch/Approval:

In July 2022, Dr. Reddy’s Laboratories Ltd., a global pharmaceutical company headquartered in Hyderabad, India, announced the first-to-market launch of over-the-counter (OTC) Fexofenadine HCl 180 mg and Pseudoephedrine HCl 240 mg Extended Release Tablets, USP, the store-brand equivalent of Allegra-D® 24 HR in the U.S. market, as approved by the U.S. Food and Drug Administration (USFDA).